• Includes 4 antigens which help achieve broad coverage 6
• Real world experience – including immunisation programs for infants 7, 8
• Flexible dosing options that fit with routine vaccination visits 5
• Prophylactic paracetamol is recommended when BEXSERO is given to children < 2 years of age, regardless of the presence of fever 4
• In infants and toddlers, the most common adverse reactions were tenderness and erythema at the injection site, fever and irritability 5
TELL PARENTS ABOUT MENINGOCOCCAL B AND HOW BEXSERO CAN HELP PROTECT THEIR VULNERABLE INFANTS * 5
* Indicated from 2 months of age. 5
Multicomponent Meningococcal group B vaccine( recombinant, adsorbed)
The only meningococcal B vaccine indicated from 2 months of age, offering the broadest age indication to help protect those most at risk. 5
• Includes 4 antigens which help achieve broad coverage 6
• Real world experience – including immunisation programs for infants 7, 8
• Flexible dosing options that fit with routine vaccination visits 5
• Prophylactic paracetamol is recommended when BEXSERO is given to children < 2 years of age, regardless of the presence of fever 4
• In infants and toddlers, the most common adverse reactions were tenderness and erythema at the injection site, fever and irritability 5
PBS Information: This product is not listed on the National Immunisation Program( NIP). This product is not listed on the PBS.
Please review BEXSERO Product Information before prescribing. Full Product Information is available at au. gsk. com
Bexsero ® Minimum Product Information Multicomponent Meningococcal group B vaccine( recombinant, adsorbed). Indications: Active immunisation against invasive disease caused by N. meningitidis group B from 2 months of age. Contraindications: Hypersensitivity to any vaccine component. Precautions: Bexsero should never be administered intravenously, subcutaneously or intradermally. Postpone vaccination during acute severe febrile illness. Apnoea in very premature infants. Anticipate psychogenic response( syncope, hyperventilation). Anticipate fever( prophylactic paracetamol). Immune response may be reduced in immunocompromised Individuals. No data for use in subjects aged ≥50 years. Limited data in patients with chronic medical conditions. Kanamycin-sensitive individuals. Pregnancy( category B1). Lactation. Safe use in latex sensitive individuals not established. Interactions: Can be given with DTPa, Hib, IPV, HepB, PCV7, MenC-CRM, MMR and V. Immunogenicity of Bexsero or routine vaccines is unaffected by prophylactic paracetamol. Bexsero must be administered at separate injection sites. Adverse reactions: Infants, Toddlers & Children( up to 10 years): eating disorders, sleepiness, unusual crying, diarrhoea, vomiting, rash, fever( ≥39.5 ° C), injection site reactions, irritability. Adolescents( from 11 years) & Adults: headache, nausea, injection site reactions, malaise, myalagia, arthralgia. This is not a full list. Dosage and Administration: Administered by deep intramuscular injection. 0.5ml dose in a pre-filled syringe. Infants( 2 – 5 months): 3 doses( ≥1 month interval), booster dose at 12 – 23 months. Unvaccinated infants( 6 – 11 months): 2 doses( ≥2 month interval), booster dose at 12 – 23 months( ≥2 month interval between primary series and booster). Unvaccinated toddlers and children( 12 months – 10 years): 2 doses( ≥2 month interval), need for booster not established. 11 – 50 years: 2 doses( ≥1 month interval), need for booster not established. Storage: Between + 2 ° C and 8 ° C. DO NOT FREEZE. Protect from light. For further information, please refer to the full PI. [ Bexsero min PI v03 ]. References: 1. Face to face market research conducted by IMS; Sept 2016 N = 20 Australian mothers with a child between the age of 6 weeks and < 1 year. Purpose: To identify awareness, information sources of vaccination and decision-making factors. Data on file: AUS / BEX / 0051 / 16. 2. Online market research conducted by IPSOS South Australian Meningococcal Disease Awareness Campaign Survey February 2018, N = 865 participants from the general population and parents of children aged 0-17 years. Data on file AUS / VAC / 0009 / 18. 3. Australian Government Department of Health. Invasive meningococcal disease national surveillance report. Available from: http:// www. health. gov. au / internet / main / publishing. nsf / content / cda-pubs-annlrpt-menganrep. htm Accessed on: 17.07.18. 4. Australian Technical Advisory Group on Immunisation( ATAGI). The Australian Immunisation Handbook 10th ed( 2017 update). Canberra: Australian Government Department of Health, 2017. 5. Bexsero Approved Product Information. 6. Vesikan T et al. Lancet 2013; 381: 825 – 35. 7. Meningococcal B. National Immunisation Office website. https:// www. hse. ie / eng / health / immunisation / hcpinfo / othervaccines / meningococcalb /. Accessed 3 May 2018. 8. Piano Nazionale Prevenzione Vaccinale PNPV 2017 – 2019. Ministero della salute website. http:// www. salute. gov. it / imgs / C _ 17 _ pubblicazioni _ 2571 _ allegato. pdf. Accessed 3 May 2018. For information on GSK products or to report an adverse event involving a GSK product, please contact GSK Medical Information on 1800 033 109. GlaxoSmithKline Australia Pty Ltd. ABN 47 100 162 481. Melbourne, VIC. Trade marks are owned by or licensed to the GSK group of companies © 2018 GSK group of companies or its licensor. AUS / BEX / 0031 / 18a. Date of approval August 2018. BEX0105.